Home › Funds › Kimelman & Baird, LLC › ABBV
Kimelman & Baird, LLC position in ABBV
ABBVIE INC · Health Care
Kimelman & Baird, LLC reported holding 30,556 shares of ABBV (ABBVIE INC) in its Q3 2026 13F filing — a position valued at US$8.0M, representing 0.60% of its reported portfolio and ranking #39 among its reported holdings. Kimelman & Baird, LLC has disclosed ABBV holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-04 · Source: SEC EDGAR Form 13F-HR
How Kimelman & Baird, LLC's ABBV position evolved
Kimelman & Baird, LLC first disclosed a stake in ABBV in Q2 2024 at 33,766 shares (US$5.8M). The position peaked in Q3 2026 at 30,556 shares, worth US$8.0M. Across 10 filings, Kimelman & Baird, LLC increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 7 time(s). The most recent filing (Q3 2026) shows 30,556 shares valued at US$8.0M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 33.77K | $5.79M | New |
| Q3 2024 | 33.77K | $6.67M | Hold |
| Q4 2024 | 31.07K | $5.52M | Reduce |
| Q1 2025 | 31.07K | $6.51M | Hold |
| Q2 2025 | 31.07K | $5.77M | Hold |
| Q3 2025 | 31.07K | $7.19M | Hold |
| Q4 2025 | 30.66K | $7.00M | Reduce |
| Q1 2026 | 30.66K | $6.67M | Hold |
| Q2 2026 | 30.66K | $7.71M | Hold |
| Q3 2026 | 30.56K | $7.99M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABBV and 13F data
ABBV (ABBVIE INC) is a Health Care company. 35 other funds we track also report a position in ABBV — the largest reported positions include Vanguard Group (US$41.31B), BlackRock Inc (US$37.62B), VANGUARD CAPITAL MANAGEMENT LLC (US$29.04B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABBV
- Vanguard Group 180.78M sh · $41.31B · Q4 2025
- BlackRock Inc 149.49M sh · $37.62B · Q2 2026
- VANGUARD CAPITAL MANAGEMENT LLC 115.40M sh · $29.04B · Q2 2026
- Banque Cantonale Vaudoise 89.31K sh · $22.47B · Q2 2026
- STATE STREET CORP 81.22M sh · $17.66B · Q1 2026
- VANGUARD PORTFOLIO MANAGEMENT LLC 48.48M sh · $12.20B · Q2 2026
- GEODE CAPITAL MANAGEMENT, LLC 47.00M sh · $11.81B · Q2 2026
- Geode Capital Management 47.00M sh · $11.81B · Q2 2026
- Morgan Stanley 38.90M sh · $9.79B · Q2 2026
- Capital Research Global Investors 30.10M sh · $7.57B · Q2 2026
- Capital Research Global Investors 30.10M sh · $7.57B · Q2 2026
- Norges Bank Investment Management 25.55M sh · $6.43B · Q2 2026
More on Kimelman & Baird, LLC
FAQ
How long has Kimelman & Baird, LLC held ABBV?
Kimelman & Baird, LLC has disclosed ABBV holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
What is Kimelman & Baird, LLC's current position in ABBV?
As of Q3 2026, Kimelman & Baird, LLC holds 30.56K shares of ABBV (ABBVIE INC), valued at $7.99M, representing 0.60% of its reported portfolio and ranking #39.
Has Kimelman & Baird, LLC been buying or selling ABBV?
In the latest 13F filing (Q3 2026), Kimelman & Baird, LLC held unchanged its position in ABBV. The position peaked in Q3 2026 at 30.56K shares.
Which other funds hold ABBV?
Other major institutional holders of ABBV include Vanguard Group, BlackRock Inc, VANGUARD CAPITAL MANAGEMENT LLC, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.